OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

BIOMARIN PHARMACEUTICAL/  US09061G1013  /

Euronext Milan
16/04/2024  17:00:30 Chg. - Volume Bid17:35:05 Ask17:35:05 Market Capitalization Dividend Y. P/E Ratio
85.90EUR - 60
Turnover: 5,160.60		 -Bid Size: - -Ask Size: - 13.55 bill.EUR - -
GlobeNewswire 08/05 Terns Pharmaceuticals Announces Leadership Changes
GlobeNewswire 02/11/2023 California Life Sciences announces 20th annual Pantheon Award winners
GlobeNewswire 02/10/2023 California’s top scientific innovators selected as finalists for the 20th annual California Life Sci...
GlobeNewswire 01/03/2022 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corpor...
GlobeNewswire 14/02/2022 Vaxart Appoints Edward Berg as Senior Vice President and General Counsel
Newsfile Corp 04/02/2022 SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.
GlobeNewswire 24/01/2022 SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.
GlobeNewswire 23/12/2021 Lifshitz Law Firm, P.C. Announces Investigations of Amarin Corporation plc (NASDAQGM: AMRN), BioMari...
GlobeNewswire 21/12/2021 BMRN FINAL DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages BioMarin Pharmaceutical Inc....
GlobeNewswire 20/12/2021 BMRN & RECAF – Upcoming Lead Deadlines: Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire 20/12/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...
GlobeNewswire 17/12/2021 ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure C...
GlobeNewswire 07/12/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...
GlobeNewswire 07/12/2021 ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Befor...
GlobeNewswire 01/12/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...
GlobeNewswire 30/11/2021 AMRN, BMRN & RECAF – Upcoming Class Actions Deadlines: Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire 28/11/2021 ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losse...
GlobeNewswire 19/11/2021 AMRN, BMRN & RECAF – Class Actions Deadlines: Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire 15/11/2021 Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
GlobeNewswire 13/11/2021 ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Lo...
GlobeNewswire 12/11/2021 AMRN, BMRN & RECAF – Class Action Alerts: Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire 10/11/2021 INVESTOR REMINDER: BIOMARIN PHARMACEUTICAL INC. (NASDAQ: BMRN) SHAREHOLDER CLASS ACTION DEADLINE- Be...
GlobeNewswire 09/11/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...
GlobeNewswire 09/11/2021 BIOMARIN DEADLINE ALERT: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Enco...
GlobeNewswire 03/11/2021 BMRN INVESTOR NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutica...